PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Chowdhury, Ferdousi ^a   Dunn, Stuart ^a   Mitchell, Simon ^a   Mellows, Toby ^b   Ashton Key, Margaret ^a,b   Gray, Juliet C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CD8; immunotherapy; PD 1; PD L1; pediatric tumor microenvironment

Indexed keywords

CD8 ANTIGEN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG TARGETING; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SCHOOL CHILD; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84940702735     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1029701     Document Type: Article

References (22)

1. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
2. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
3. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
4. A.L.Yu, A.L.Gilman, M.F.Ozkaynak, W.B.London, S.G.Kreissman, H.X.Chen, M.Smith, B.Anderson, J.G.Villablanca, K.K.Matthay, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
5. F.Berthold, J.Boos, S.Burdach, R.Erttmann, G.Henze, J.Hermann, T.Klingebiel, B.Kremens, F.H.Schilling, M.Schrappe, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6:649-58; PMID:16129365; http://dx.doi.org/10.1016/S1470-2045(05)70291-6
6. W.B.London, V.Castel, T.Monclair, P.F.Ambros, A.D.Pearson, S.L.Cohn, F.Berthold, A.Nakagawara, R.L.Ladenstein, T.Lehara, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011; 29:3286-92; PMID:21768459; http://dx.doi.org/10.1200/JCO.2010.34.3392
7. J.R.Brahmer, C.G.Drake, I.Wollner, J.D.Powderly, J.Picus, W.H.Sharfman, E.Stankevich, A.Pons, T.M.Salay, T.L.McMiller, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
8. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
9. D.L.Barber, E.J.Wherry, D.Masopust, B.Zhu, J.P.Allison, A.H.Sharpe, G.J.Freeman, R.Ahmed. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7, 2006; PMID:16382236; http://dx.doi.org/10.1038/nature04444
10. M.E.Keir, S.C.Liang, I.Guleria, Y.E.Latchman, A.Qipo, L.A.Albacker, M.Koulmanda, G.J.Freeman, M.H.Sayegh, A.H.Sharpe. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203:883-95; PMID:16606670; http://dx.doi.org/10.1084/jem.20051776
11. T.Nomi, M.Sho, T.Akahori, K.Hamada, A.Kubo, H.Kanehiro, S.Nakamura, K.Enomoto, H.Yagita, M.Azuma, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7; PMID:17404099; http://dx.doi.org/10.1158/1078-0432.CCR-06-2746
12. R.H.Thompson, S.M.Kuntz, B.C.Leibovich, H.Dong, C.M.Lohse, W.S.Webster, S.Sengupta, I.Frank, A.S.Parker, H.Zincke, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381-5; PMID:16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
13. S.Muenst, A.R.Schaerli, F.Gao, S.Däster, E.Trella, R.A.Droeser, M.G.Muraro, P.Zajac, R.Zanetti, W.E.Gillanders, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146:15-24; PMID:24842267; http://dx.doi.org/10.1007/s10549-014-2988-5
14. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
15. L.S.van Dam, V.M.de Zwart, F.A.Meyer-Wentrup. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. Pediatr Blood Cancer 2015; 62:190-7
16. R.H.Thompson, M.D.Gillett, J.C.Cheville, C.M.Lohse, H.Dong, W.S.Webster, K.G.Krejci, J.R.Lobo, S.Sengupta, L.Chen, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci 2004; 101:17174-9; PMID:15569934; http://dx.doi.org/10.1073/pnas.0406351101
17. B.J.Chen, B.Chapuy, J.Ouyang, H.H.Sun, M.G.Roemer, M.L.Xu, H.Yu, C.D.Fletcher, G.J.Freeman, M.A.Shipp, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19:3462-73; PMID:23674495; http://dx.doi.org/10.1158/1078-0432.CCR-13-0855
18. J.R.Kim, Y.J.Moon, K.S.Kwon, J.S.Bae, S.Wagle, K.M.Kim, H.S.Park, H.Lee, W.S.Moon, M.J.Chung, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE 2013; 8(12): e82870; PMID:24349382; http://dx.doi.org/10.1371/journal.pone.0082870
19. J.M.Taube, R.A.Anders, G.D.Young, H.Xu, R.Sharma, T.L.McMiller, S.Chen, A.P.Klein, D.M.Pardoll, S.L.Topalian, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127-37; http://dx.doi.org/10.1126/scitranslmed.3003689
20. J.Chen, Y.Feng, L.Lu, H.Wang, L.Dai, Y.Li, P.Zhang. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012; 217(4):385-93; PMID:22204817; http://dx.doi.org/10.1016/j.imbio.2011.10.016
21. K.Abiko, M.Mandai, J.Hamanishi, Y.Yoshioka, N.Matsumura, T.Baba, K.Yamaguchi, R.Murakami, A.Yamamoto, B.Kharma, et al. PD-L1 on tumour cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Can Res 2013; 19:1363-74; PMID:23340297; http://dx.doi.org/10.1158/1078-0432.CCR-12-2199
22. H.Kronig, L.Kremmler, B.Haller, C.Englert, C.Peschel, R.Andreesen, C.U.Blank. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 2014; 92(3):195-203; PMID:24175978; http://dx.doi.org/10.1111/ejh.12228